Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.

Alumis is a precision medicines company looking to eliminate the ‚Äúall-comers‚Äù approach that is seen with today‚Äôs treatments for people with autoimmune disease. Even with the innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of their disease without life-impacting side effects. Esker leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.

Alumis

Associate Director, Quality Assurance

Associate Director, GMP Quality Assurance

Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company.

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

Tarsus Pharmaceuticals

Assoc Dir, Quality Assurance

Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.

Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company‚Äôs cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte‚Äôs proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

Vaxcyte

Associate Director, Quality Assurance, Compliance

Associate Director, Quality Assurance, CMO

Wonder is a food delivery startup that operates truck-based restaurants from which consumers can order food through a mobile app.

Wonder is a food delivery startup that operates truck-based restaurants from which consumers can order food through a mobile app. Wonder trucks drive to a location near the user‚Äôs home and prepare an order on-site to ensure fresh deliveries.

Wonder

Associate Director, Food Safety and Quality Assurance

MobLabs

Travere discovers and develops drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening.

Travere Therapeutics is advancing therapeutic candidates for rare disorders in nephrology, hepatology and metabolism; sponsoring no-cost genetic testing aimed at improving the diagnostic odyssey for children born with cholestasis; partnering with patient advocacy organizations to meet the diverse needs of patients and their families; and ensuring broad access and education for its FDA-approved therapies.

Travere Therapeutics

Associate Director, Quality Assurance GCP/GLP (San Diego, CA or Remote)

Synthego is a genome engineering company that enables access to CRISPR to accelerate life science research and development.

Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company‚Äôs full-stack platform vertically integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs. By providing both commercial and academic researchers and therapeutic developers with unprecedented access to cutting-edge genome engineering, Synthego is at the forefront of innovation, accelerating the development of truly engineered biology. The company was founded in 2012 and is based in Redwood City, California.

Synthego

Quality Assurance - Associate Director, Quality Systems & Compliance (QSC)

X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.

X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment. The company is developing two unique programs such as drug candidate, X4P-001, has clinical experience in over 70 subjects, and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC), the second program, X4P-002, is a unique series of late lead molecules that penetrate the blood-brain barrier. They will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program.

X4 Pharmaceuticals

Associate Director, GCP Quality

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer‚Äôs disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector‚Äôs strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.

Location

Company Stage

Age of Data

Experience

Industry

Company

Associate Director, Quality Assurance

Alumis

$180k - $205k

$180,000 - $205,000

Tarsus Pharmaceuticals

$139k - $194k

$138,700 - $194,300

Vaxcyte

$182k - $192k

$182,000 - $192,000

Wonder

$184k

$183,750

MobLabs

$184k

$183,750

Travere Therapeutics

$132k - $182k

$132,000 - $182,000

Synthego

$160k - $180k

$160,000 - $180,000

X4 Pharmaceuticals

N/A

N/A

Alector

N/A

N/A